This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
To determine the measurable value of long-term anticoagulant therapy after myocardial infarction, four physicians at the University of Oregon Medical School in Portland instituted a controlled double-blindfold study seven years ago.
That study is still in progress, and to date has involved 200 patients. Although a final report is not yet being considered, the principal investigator, Arthur J. Seaman, MD, presented a progress report at the International Symposium on Anticoagulants at Miami Beach last month. His observations on the experiment:
"As yet no reduction in death rate or overall decrease in morbidity has been shown to be conferred by continuous prophylactic anticoagulant therapy post-myocardial infarction."
Seaman, whose colleagues include Herbert E. Griswold, MD, Balph B. Beaume, MD, and Leonard W. Ritzmann, MD, said the trend of the results after sequential analysis has moved in the direction of the as yet unreached conclusion that there is "no difference between anticoagulant therapy and placebo (or control) treatment."
Deaths, Morbidity Not Reduced Thus Far, Oregon Study Shows. JAMA. 1964;187(7):30. doi:10.1001/jama.1964.03060200094048
Customize your JAMA Network experience by selecting one or more topics from the list below.